Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brenipatide for Reduction in Risk of Relapse to Cigarette Smoking
NCT07223840Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2025
- Primary completion
- Feb 2027
- Modality
- Peptides
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Tobacco Use Disorder (TUD) comparing Brenipatide with Placebo (2 arms). Primary endpoint: Percentage of Participants that Achieve Carbon Monoxide (CO)-Confirmed Continuous Abstinence from Cigarette Smoking with Allowed Slips at 24 weeks. Started Nov 2025; status: recruiting.
02
Drugs
brenipatide
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT07223840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223840.